Related Experiment Video

Updated: May 10, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer

Wei Gao1, John Zeng Hong Li, Jimmy Yu Wai Chan

  • 1Department of Surgery, The University of Hong Kong and Queen Mary Hospital, 102 Pokfulam Road, Hong Kong.

ISRN Otolaryngology
|June 14, 2013
PubMed

Insights

Targeting the mTOR pathway shows promise for head and neck cancer treatment. mTOR inhibitors are effective in preclinical models and are being evaluated in clinical trials for this common cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Head and neck cancer is a significant global health concern, ranking sixth in incidence worldwide.
  • Conventional treatments often lack selectivity, leading to systemic toxicities.
  • The mammalian target of rapamycin (mTOR) signaling pathway is frequently activated in head and neck cancers, presenting a therapeutic target.

Purpose of the Study:

  • To investigate the potential of targeting the mTOR signaling pathway for head and neck cancer therapy.
  • To explore the diagnostic and prognostic value of mTOR and its downstream targets in head and neck cancer.
  • To review the efficacy of mTOR inhibitors in preclinical and clinical settings for head and neck cancer.

Main Methods:

  • Review of scientific literature on mTOR signaling in head and neck cancer.
  • Analysis of preclinical data from in vitro cell line and in vivo xenograft models.
  • Examination of ongoing and completed clinical trials evaluating mTOR inhibitors.

Main Results:

  • mTOR pathway activation is a hallmark of head and neck cancer.
  • Expression levels of mTOR and downstream targets (eIF4E, 4EBP1, S6K1, S6) may serve as biomarkers.
  • mTOR inhibitors (rapamycin, temsirolimus, everolimus) demonstrated inhibitory effects on head and neck cancer models.
  • Numerous clinical trials are underway to assess mTOR inhibitors' therapeutic potential.

Conclusions:

  • mTOR inhibitors represent a promising targeted therapy for head and neck cancer.
  • These inhibitors can be used as monotherapy or in combination with other treatments for synergistic effects.
  • Further clinical evaluation is warranted to establish the role of mTOR inhibitors in head and neck cancer management.

More Related Videos

Multi-photon Imaging of Tumor Cell Invasion in an Orthotopic Mouse Model of Oral Squamous Cell Carcinoma12:03

Multi-photon Imaging of Tumor Cell Invasion in an Orthotopic Mouse Model of Oral Squamous Cell Carcinoma

Published on: July 25, 2011

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...